0%, 100%, then 200%: How Trump's new generic drug tariff plan could hit India
The story in brief
The US is considering new tariffs on pharmaceutical imports from India and other countries, part of Trump's strategy to boost domestic manufacturing. Indian generics supply 47% of US prescriptions, saving $1.3 trillion over a decade. US Trade Representative Greer hinted at more tariffs, with the temporary 10% blanket tariff on imports set to expire later this week. The move comes amid broader trade tensions.